Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Date

21 January 2020

Antibiotic resistance: more companies are withdrawing sales reps or incentives in order to limit use, finds report

Writing for the British Medical Journal, Elisabeth Mahase covers the results of the second Antimicrobial Resistance Benchmark. In the article, the author looks at where companies are making progress and where improvements are still needed.

Direct links

Read the full article

The article begins with a quote from Jayasree K Iyer, Executive Director of the Access to Medicine Foundation, calling on governments and the pharmaceutical industry to take the current AMR situation seriously and work together to solve it:

“We’re not asking for a scientific miracle here, we are asking for human intervention.”

The article then dives deep into the results of the 2020 Antimicrobial Resistance Benchmark, covering topics like antibacterial R&D, progress in responsible promotion, and tracking the spread of resistance.

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved